Comparative Pharmacology
Head-to-head clinical analysis: PHOSLYRA versus RENAGEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PHOSLYRA versus RENAGEL.
PHOSLYRA vs RENAGEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phoslyra (calcium acetate) binds dietary phosphate in the gastrointestinal tract, forming insoluble calcium phosphate complexes that are excreted in the feces, thereby reducing serum phosphate levels.
Sevelamer is a phosphate-binding polymer that binds dietary phosphate in the gastrointestinal tract, preventing its absorption and reducing serum phosphate levels.
1330 mg (one caplet) orally three times daily with meals, titrated to achieve serum phosphorus within target range.
Initial dose: 800-1600 mg orally three times daily with meals. Titrate by 1 tablet/capsule per meal based on serum phosphorus levels. Maintenance: typically 2-4 tablets/capsules per meal.
None Documented
None Documented
Not applicable; Phoslyra (calcium acetate) is not absorbed systemically; local effect in GI tract.
Not applicable (non-absorbable polymer; systemic absorption <0.01%).
Renal 100% as unchanged drug, no biliary or fecal elimination.
Renal: 0%; Fecal: >99% (as intact drug, due to non-absorbable polymer). Biliary: negligible.
Category C
Category C
Phosphate Binder
Phosphate Binder